LGBTQ+ Health Fellow and Clinical Instructor of Medicine at UCLA
Department of Internal Medicine and Pediatrics; David Geffen School of Medicine at UCLA
Los Angeles, CA, United States
Dr. Alexander Kaplan (he/him) is an LGBTQ+ Healthcare Fellow (2025-2026) at UCLA. His clinical interests encompass LGBTQIA+ primary care, gender-affirming care, HIV and STI prevention/management, and anorectal cancer screening. He is also passionate about medical education, the integration of humanism in clinical practice, and research addressing social determinants of health affecting the LGBTQIA+ community.
Originally from Massachusetts and Florida, Dr. Kaplan earned his undergraduate degree from Hamilton College, double majoring in Biochemistry & Molecular Biology and Hispanic Studies. He later worked as the translational research coordinator in neuro-oncology at Massachusetts General Hospital. While interacting with patients in his research role, he became passionate about sexual and gender minority health and reducing disparities for this population within the healthcare system.
He earned his medical degree from the University of Massachusetts Chan Medical School in the PURCH Track and was inducted into the Gold Humanism Honor Society. During his time at UMass Med, Dr. Kaplan held leadership roles in multiple LGBTQIA+ student organizations and developed a curriculum aimed at advancing health advocacy for LGBTQIA+ communities.
Dr. Kaplan completed his internal medicine residency at Emory University School of Medicine in the Primary Care Track in 2025, with additional training in HIV care through the HIV Area of Distinction. His research focused on disparities in access to long-acting injectable cabotegravir (LAI-CAB) pre-exposure prophylaxis and interrogating reasons for discontinuation of LAI-CAB. During residency, Dr. Kaplan developed peer education lectures on DoxyPEP, LAI-CAB, and preventive care for gender-diverse patients.
In his free time, he enjoys photography, glassblowing, hiking, and exploring his new home in Los Angeles/California.
Disclosure information not submitted.
573 - Discontinuation of Cabotegravir for PrEP: Challenges and Opportunities
Wednesday, October 22, 2025
10:42 AM - 10:54 AM US ET